Irbesartán/Hidroclorotiazida Cinfa

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartán/Hidroclorotiazida Cinfa, is an angiotensin II receptor blocker and thiazide diuretic presented as a tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Irbesartán/Hidroclorotiazida Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used to manage high‑blood‑pressure conditions within the antihypertensive drug class. - Essential hypertension: lowers systolic and diastolic blood pressure to target levels. - Hypertension requiring diuretic therapy: adds diuretic effect to improve blood‑pressure control. - Hypertension with fluid retention: reduces plasma volume and vascular resistance for better control.

Adverse reactions may occur with any antihypertensive combination therapy.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Fatigue. - Increased urination. - Electrolyte disturbances (e.g., low potassium). - Mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension. - Acute kidney injury. - Hyperkalemia. - Angioedema. - Hepatic dysfunction. - Severe electrolyte imbalance (e.g., hyponatremia).

Before initiating therapy, consider the following safety measures. - Renal impairment: monitor kidney function and adjust therapy as needed. - Electrolyte balance: check serum potassium and sodium regularly. - Pregnancy: avoid use unless clearly needed; discuss risks with a healthcare professional. - Concomitant drugs: review all medications for potential interactions. - Elderly patients: start at lower doses and monitor closely for orthostatic effects. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Irbesartan/Hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Lithium: increased lithium levels and toxicity. - NSAIDs: may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: additive risk of renal dysfunction. - Antidiabetic agents: may require dose adjustment due to blood‑glucose changes. - Antihypertensive agents (beta‑blockers, calcium channel blockers): monitor for excessive blood‑pressure lowering.